You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Acromegaly: For the symptomatic control and reduction of growth hormone and IGF-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with Sandostatin. Sandostatin LAR is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,Gastro-entero-pancreatic tumours: For the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - Carcinoid tumours with features of the carcinoid syndrome; - Vasoactive intestinal peptide secreting tumours (VIPomas) in patients who are adequately controlled on subcutaneous treatment with Sandostatin.
Sandostatin LAR is not curative in these patients.,Advanced neuroendocrine tumours of the midgut: Treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Acromegaly: For the symptomatic control and reduction of growth hormone and IGF-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with Sandostatin. Sandostatin LAR is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,Gastro-entero-pancreatic tumours: For the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - Carcinoid tumours with features of the carcinoid syndrome; - Vasoactive intestinal peptide secreting tumours (VIPomas) in patients who are adequately controlled on subcutaneous treatment with Sandostatin.
Sandostatin LAR is not curative in these patients.,Advanced neuroendocrine tumours of the midgut: Treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Acromegaly: For the symptomatic control and reduction of growth hormone and IGF-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with Sandostatin. Sandostatin LAR is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,Gastro-entero-pancreatic tumours: For the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - Carcinoid tumours with features of the carcinoid syndrome; - Vasoactive intestinal peptide secreting tumours (VIPomas) in patients who are adequately controlled on subcutaneous treatment with Sandostatin. Sandostatin LAR is not curative in these patients.,Advanced neuroendocrine tumours of the midgut: Treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
